Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VolitionRx Limited (VNRX) SEC filings page provides direct access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, periodic reports, and registration-related documents. As a NYSE American-listed issuer, VolitionRx uses these filings to report material agreements, capital-raising transactions, governance changes, and other significant events related to its epigenetics and diagnostic testing business.
Recent Forms 8-K describe several key financing arrangements, such as an amended and restated securities purchase agreement with an institutional investor involving a senior secured convertible promissory note and common stock purchase warrant, underwritten public offerings of common stock and warrants, and a registered direct offering of shares and warrants to existing stockholders and insiders. Other 8-K filings detail amendments to the company’s certificate of incorporation to increase authorized common stock, results of stockholder votes at the annual meeting, and announcements of quarterly financial results and business updates.
These filings also outline the terms of VolitionRx’s securities, including conversion prices, warrant exercise prices, ownership limitations, repayment schedules, security interests in company assets, and conditions that constitute events of default. Investors can review how the company structures its capital, secures funding for research and commercialization of its Nu.Q® and related platforms, and manages its obligations to lenders and underwriters.
On Stock Titan, each VolitionRx filing is accompanied by AI-powered summaries that highlight the most important points, such as new financing terms, changes to authorized share capital, or disclosure of financial results. Users can quickly see which filings relate to earnings (often furnished under Item 2.02), which involve material definitive agreements (Item 1.01), and which concern governance or charter amendments (Items 5.02 and 5.03). This structure helps readers navigate lengthy documents and focus on the aspects most relevant to their analysis of VNRX.
VolitionRx Ltd (VNRX) insider tax-withholding share cancellation
The company reported that on 10/04/2025 12,333 shares of common stock were disposed of under Transaction Code F at a reported price of $0.648 per share. The filing explains these shares represent the portion of 24,666 restricted stock units settled for the reporting person that were retained by VolitionRx for cancellation to satisfy tax-withholding obligations. The reporting person, Gaetan Michel, is listed as Chief Operating Officer and a director; the form states that no shares were sold by the reporting person or by VolitionRx in connection with this withholding arrangement.
VolitionRx Ltd. reporting person Jacob Vincent Micallef, Chief Scientific Officer and director, reported a non‑derivative transaction on 10/04/2025 that reduced his direct common stock holdings by 5,850 shares at a price of $0.648 per share. The form states these 5,850 shares represent the portion of shares retained by the company to satisfy tax withholding upon settlement of 13,000 restricted stock units (RSUs); no shares were sold by the reporting person. After the transaction he beneficially owns 393,089 shares directly, plus 55,000 shares held by his spouse and 38,113 shares held by Borlaug Limited, a company he controls. The filing is informational and documents insider ownership and the tax‑withholding mechanics tied to RSU settlement.
Rodney Gerard Rootsaert, a reporting officer and director of VolitionRx Ltd (VNRX), reported a transaction dated 09/28/2025 involving restricted stock units. To satisfy tax withholding on the settlement of 9,900 restricted stock units, VolitionRx retained 4,158 common shares (transaction code F) at an indicated per-share price of $0.605; no open-market sale occurred. After the withholding, the reporting person beneficially owns 145,075 shares directly. In addition, Concord International, Inc. holds 1,007,718 shares indirectly; Rootsaert is a controlling director of Concord and shares voting and dispositive control. The Form 4 indicates shares were retained by the company for tax withholding and clarifies ownership forms but does not show any derivative transactions.
Salvatore Thomas Butera, listed as an officer (CEO - Volition Veterinary) and director of VolitionRx Ltd (VNRX), reported transactions dated 09/28/2025 on a Form 4. The filing shows 5,230 shares of common stock disposed of at $0.605 per share by means of share retention by the issuer to satisfy tax withholding on the settlement of 19,125 restricted stock units; the filing states no shares were sold by the reporting person or the company. The reporting person beneficially owns 332,285 shares following the transaction, and 99,350 shares are jointly owned with his spouse.
Jacob Vincent Micallef, Chief Scientific Officer and director of VolitionRx Ltd (VNRX), reported a Section 16 transaction dated 09/28/2025. The filing shows 5,568 shares of common stock disposed at $0.605 per share under transaction code F. The filer states these shares were retained by VolitionRx to satisfy tax withholding obligations on the settlement of 12,375 restricted stock units, and explicitly notes that no shares were sold by the reporting person or VolitionRx in that transaction.
Following the reported transaction, the reporting person beneficially owns 398,939 shares directly, plus 55,000 shares held indirectly by spouse and 38,113 shares held by Borlaug Limited (the reporting person is the controlling director of Borlaug Limited with voting and dispositive control). The form is a routine insider disclosure of ownership changes related to equity compensation tax withholding.
Ann-Louise Batchelor, Group Chief Marketing Officer of VolitionRx Ltd (VNRX), reported a transaction dated 09/28/2025 on Form 4 in which 5,604 shares of common stock were disposed of under code F at a price of $0.605 per share. The filing shows 154,282 shares beneficially owned directly after the transaction and 29,406 shares indirectly beneficially owned through her spouse.
The filing explanation states these 5,604 shares represent the portion of 11,925 restricted stock units whose shares were retained by VolitionRx and cancelled to satisfy the reporting person’s tax withholding obligations upon settlement. The form clarifies that no shares were sold by the reporting person or by VolitionRx in connection with the withholding.
VolitionRx insider filing: Michel Gaetan, the company's Chief Operating Officer and a director, reported a transaction dated 09/28/2025 reducing his direct common stock holding. The Form 4 shows a Code F disposition of 11,362 shares at $0.605, leaving 369,079 shares beneficially owned directly after the reported transaction. The filing explains these 11,362 shares represent the portion of 22,725 restricted stock units retained by VolitionRx to satisfy tax withholding upon settlement; the form states no shares were sold by the reporting person or the company in the process. The form is signed by Gaetan on 09/30/2025.
Gael Forterre, Chief Commercial Officer and reporting person for VolitionRx Ltd (VNRX), reported a transaction dated 09/28/2025 that reduced his direct common stock holdings by 5,503 shares at a price of $0.605 per share. The filing explains these 5,503 shares were retained by the issuer to satisfy tax withholding obligations upon settlement of 13,725 restricted stock units; no shares were sold by Mr. Forterre or VolitionRx. After the reported transaction he beneficially owns 160,924 shares directly, plus 5,000 shares held by his spouse and 32,500 shares managed by Armorica Partners, LLC, for which he is the managing director and sole shareholder.
Cameron John Reynolds, President and CEO and a director of VolitionRx Ltd (VNRX), reported an open-market purchase of common stock on 09/12/2025. He acquired 15,000 shares at $0.659 per share. After the transaction he directly beneficially owns 2,624,847 shares and indirectly owns 1,007,718 shares through Concord International, Inc.; an additional 34,076 shares are held indirectly by his spouse.
The Form 4 is signed on 09/15/2025. The filing notes Reynolds is majority shareholder of Concord International, Inc., sharing voting and dispositive control over those shares.
Terig Hughes, Chief Financial Officer and Director of VolitionRX Limited (VNRX), was awarded 26,143 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation. The Form 4 shows the RSUs were granted at a price of $0 and the reporting person beneficially owned 533,770 shares following the award. The RSUs are earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, remain subject to additional time-based vesting in two installments of 13,072 units on 11/01/2025 and 13,071 units on 02/01/2026. The award is subject to continued service through each earning and vesting date and will settle into a like number of common shares upon vesting.